SELLAS Life Sciences (SLS) Total Liabilities (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Total Liabilities for 9 consecutive years, with $10.6 million as the latest value for Q3 2024.
- On a quarterly basis, Total Liabilities rose 177.32% to $10.6 million in Q3 2024 year-over-year; TTM through Sep 2024 was $10.6 million, a 177.32% increase, with the full-year FY2023 number at $14.2 million, down 11.79% from a year prior.
- Total Liabilities was $10.6 million for Q3 2024 at SELLAS Life Sciences, down from $12.2 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $18.1 million in Q4 2020 to a low of -$19.1 million in Q2 2022.
- A 5-year average of $10.6 million and a median of $11.8 million in 2021 define the central range for Total Liabilities.
- Peak YoY movement for Total Liabilities: crashed 286.67% in 2022, then soared 177.32% in 2024.
- SELLAS Life Sciences' Total Liabilities stood at $18.1 million in 2020, then tumbled by 67.23% to $5.9 million in 2021, then soared by 171.46% to $16.1 million in 2022, then dropped by 11.79% to $14.2 million in 2023, then decreased by 25.23% to $10.6 million in 2024.
- Per Business Quant, the three most recent readings for SLS's Total Liabilities are $10.6 million (Q3 2024), $12.2 million (Q2 2024), and $14.8 million (Q1 2024).